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Abstract TRAIL/Apo-2L induces rapid apoptosis of a variety
of tumor cell lines. A family of tumor necrosis factor receptor-
related molecules have been identified as receptors for TRAIL.
Herein, we report the identification of another member of the
TRAIL receptor family, TRUNDD (TRAIL receptor with a
truncated death domain). The TRUNDD transcript was detected
in multiple human tissues. TRUNDD is highly homologous to all
known TRAIL receptors and has an extracellular TRAIL-
binding domain but lacks a functional intracellular death domain
and does not induce apoptosis. Consistent with an inhibitory role,
ectopic expression of TRUNDD attenuated TRAIL-induced
apoptosis in mammalian cells.
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1. Introduction
Apoptosis, or programmed cell death, is an intrinsic cell
suicide mechanism of fundamental importance to develop-
ment and homeostasis in all multicellular organisms [1]. Mem-
bers of the tumor necrosis factor (TNF) ligand family, TNFK
and FasL are well-studied physiologic activators of apoptosis
and play an important role in in£ammatory and immune re-
sponses [2,3]. Recently, an additional cytotoxic ligand termed
TRAIL/Apo-2L was characterized [4,5]. TRAIL is expressed
in a variety of human tissues and induces apoptosis in many
transformed cell lines. Three receptors for TRAIL have been
identi¢ed (Fig. 4) [6^12]. DR4 and DR5 are signalling recep-
tors and fully capable of engaging the death pathway. Previ-
ously described death receptors, including TNFR1, Fas and
DR3, contain a cytoplasmic death domain that binds to the
death domain-containing adapter molecule FADD [13]. In
turn, FADD recruits and activates the apical death protease
designated caspase-8. This initiates a proteolytic cascade re-
sulting in cleavage of death substrates and eventual demise of
the cell [14]. Surprisingly, DR4 (TRAIL-R1) and DR5
(TRAIL-R2), despite containing a death domain, induce cas-
pase-dependent apoptosis independent of FADD, suggesting
the existence of another death domain-containing adapter
molecule [6^8,12]. The third receptor, TRID (DcR1/TRAIL-
R3/LIT), is a non-signalling decoy receptor that is GPI (gly-
cosyl-phosphotidylinositol)-linked to the cell surface and an-
tagonizes TRAIL-induced apoptosis [7,8,11]. DR4 and DR5
are expressed in many human tissues and cancer cell lines.
Remarkably, the decoy receptor (TRID) is di¡erentially ex-
pressed: easily detectable in normal human tissues, but not in
most tumor cell lines, consistent with a protective role in
normal tissues. In keeping with this hypothesis, overexpres-
sion of TRID protects mammalian cells from TRAIL-induced
apoptosis. Collectively, the data suggest that TRID/DcR1
may play a protective role that allows normal tissues to with-
stand the potential cytotoxic e¡ect of TRAIL.
Here we report the identi¢cation and characterization of
another TRAIL receptor, designated TRUNDD (see below).
TRUNDD is highly related to existing members of the
TRAIL receptor family and binds TRAIL. Unlike DR4 and
DR5, TRUNDD lacks a functional death domain. Ectopic
expression of TRUNDD attenuates TRAIL-induced apop-
tosis, in keeping with a role as a dominant negative recep-
tor.
2. Materials and methods
2.1. Construction of mammalian expression vectors
To facilitate detection, TRUNDD (amino acids 56^386) was cloned
into pCMV1FLAG (IBI Kodak) as an in-frame fusion to the signal
sequence and FLAG-epitope tag encoded by the vector. The cDNA
encoding the extracellular domain of TRUNDD (amino acids 56^210)
was obtained by PCR and subcloned into a modi¢ed pCMV1FLAG
vector that allowed for in-frame fusion with the Fc portion of human
IgG. DR4-Fc, TNFR1-Fc, Fc, soluble TRAIL and TNFK expression
constructs have been described previously [6].
2.2. Northern blot analysis
Human multiple tissue Northern blots (Clontech) were probed with
an internal fragment of TRUNDD cDNA according to the manufac-
turer’s instructions.
2.3. Preparation of proteins and in vitro binding assays
Receptor-Fc fusions and soluble ligands were prepared and in vitro
binding performed as previously described [6,7].
2.4. Cell death blocking assays
Blocking assays using receptor-Fc fusions were carried out as de-
scribed [6,7].
3. Results
3.1. Molecular cloning and identi¢cation of TRUNDD as a
novel TNF receptor
Homology searching of EST (expressed sequence tag)
databases with the DR5 sequence and subsequent library
screening revealed a novel cDNA clone that was identi¢ed
in four di¡erent cDNA libraries. Its open reading frame en-
coded a protein of 386 amino acids. Protein sequence compar-
ison analysis revealed the molecule to be a member of the
TNF receptor family possessing signi¢cant homology to
DR4, DR5 and TRID/DcR1 (60^70% amino acid identity)
(Fig. 1). A long putative signal sequence was present at the
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amino-terminus (amino acids 1^55) and the mature protein
was predicted to begin at amino acid 56 (Ala) [15]. Like
DR4, DR5 and TRID/DcR1, its extracellular domain (amino
acids 56^210) contained two cysteine-rich motifs characteristic
of the TNF receptor family [16]. A transmembrane domain
was present between amino acids 211 and 230. The cytoplas-
mic domain, interestingly, contained only a truncated death
domain. Thus, this novel receptor was designated TRUNDD
(TRAIL receptor with a truncated death domain).
3.2. Tissue distribution of TRUNDD transcript
To examine the tissue distribution of TRUNDD, Northern
blot analysis was performed. A single transcript was detected
in multiple human tissues at varying levels of expression (Fig.
2). PCR analysis did not reveal the existence of transcripts
that may encode an intact death domain (not shown).
3.3. TRUNDD is a TRAIL receptor
Since the entire sequence of TRUNDD, especially the ex-
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Fig. 1. Deduced amino acid sequence of TRUNDD and alignment. The nucleotide sequence is available through GenBank, accession number
AF023849. The open reading frame for TRUNDD de¢nes a type I transmembrane receptor of 386 amino acids. The mature protein is pre-
dicted to start at amino acid 56 (Ala, indicated by a black triangle). Three potential N-glycosylation sites are indicated by black dots. The ex-
tracellular cysteine-rich domain and the transmembrane domain are single- and double-underlined, respectively. The cytoplasmic death domains
are boxed. TRUNDD lacks the amino-terminal portion of the death domain.
Fig. 2. Tissue distribution of TRUNDD transcript. Human adult tissue and immune tissue RNA blots (Clontech) were probed with an internal
fragment of TRUNDD cDNA. The blots were subsequently rehybridized with L-actin cDNA. PBLs, peripheral blood leukocytes.
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tracellular cysteine-rich domains, was highly homologous to
that of other TRAIL receptors, we asked if TRAIL could
indeed bind TRUNDD. The extracellular domain of
TRUNDD was expressed as a secreted chimera fused to the
Fc portion of human IgG in 293 cells. Conditioned medium
from transfected cells was mixed with bacterially expressed
soluble His-FLAG-tagged TRAIL. The resulting complex
was precipitated with protein G-Sepharose and bound TRAIL
detected by Western blotting with anti-FLAG antibody. Like
DR4, DR5 and TRID, TRUNDD bound TRAIL (Fig. 3A).
Corroborating this ability to bind TRAIL was the ¢nding that
TRUNDD-Fc, like DR4-Fc, could e⁄ciently block TRAIL-
induced apoptosis (Fig. 3B).
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Fig. 3. The extracellular domain (ECD) of TRUNDD binds TRAIL and blocks TRAIL-induced apoptosis. A: The Fc-ECDs of TRUNDD,
DR4, TNFR1 and corresponding ligands were used in binding assays as described elsewhere [6,7]. The respective Fc fusions were precipitated
with protein G-Sepharose and coprecipitated soluble ligands detected by immunoblotting with antibody to FLAG or Myc epitopes. Bottom
panel shows the amount of input Fc fusions present in the binding assays. B: MCF7 cells were treated with soluble TRAIL (200 ng/ml, left) or
soluble TNFK (40 ng/ml, right) in the presence of equal amounts of Fc fusions or control Fc as indicated. Cells were stained with DAPI and
examined as described [6]. The data (mean þ S.D.) shown are the percentage of apoptotic nuclei among total nuclei counted (n = 3). C:
TRUNDD protects cells from TRAIL-induced apoptosis. HeLa cells were transfected with TRUNDD, CrmA expression construct or vector
alone together with a L-galactosidase reporter construct. Twenty-four hours later, TRAIL was added as indicated. Four hours later, cells were
¢xed and stained with 5-bromo-4-chloro-3-indoxyl-L-galactopyranoside and examined microscopically as described [6].
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3.4. TRUNDD antagonizes TRAIL signalling in mammalian
cells
In keeping with TRUNDD possessing a truncated non-
functional death domain (Fig. 1), its overexpression did not
induce cell death in mammalian cells (not shown), rather, as
might be expected, it could act as a dominant negative recep-
tor antagonizing TRAIL-induced apoptosis (Fig. 3C). There-
fore, ectopic expression of TRUNDD, like that of the decoy
receptor TRID substantially attenuated TRAIL-induced cell
death, suggesting that TRUNDD may function to antagonize
TRAIL signalling.
4. Discussion
TRAIL is a newly identi¢ed cytotoxic ligand that belongs
to the TNF family and rapidly induces apoptosis in a wide
variety of tumor cell lines. Unlike Fas ligand, which is pre-
dominantly expressed in activated T cells, natural killer cells
and at sites of ‘immune privilege’ including the cornea and
testis [17], TRAIL transcripts are constitutively expressed and
detectable in a variety of human tissues. Thus, TRAIL must
not be injurious to most normal tissues in vivo. Recently, a
family of TRAIL receptors have been identi¢ed (Fig. 4) [6^
12]. Like other known death receptors (including TNFR1, Fas
and DR3/Wsl/Apo3/TRAMP/LARD), DR4 and DR5 contain
a cytoplasmic death domain that is capable of engaging the
cell death pathway [13,18^22]. Paradoxically, the signalling
TRAIL receptors DR4 and DR5 are present in both normal
tissues and cancer cell lines [6^8], raising the question of why
transformed cells are sensitive but normal tissues resistant to
TRAIL-induced cell death. Identi¢cation of the third member
of the TRAIL receptor family, TRID/DcR1, provided a po-
tential solution to this conundrum. TRID/DcR1 has an ex-
tracellular TRAIL-binding domain but lacks a cytoplasmic
domain. It is expressed in normal tissues, but importantly,
not in most cancer lines. TRID acts as an antagonistic decoy
receptor since its ectopic expression protects mammalian cells
from TRAIL-induced apoptosis and its endogenous expres-
sion largely correlates with resistance to TRAIL. Therefore,
TRID/DcR1 may in part explain the non-lethality of consti-
tutively expressed TRAIL. It is not known for certain how
TRID functions to antagonize TRAIL-induced apoptosis. It
is possible that TRID simply binds and sequesters TRAIL
from the signalling receptors DR4 and DR5 or that TRID
may oligomerize with these receptors and interfere with their
capacity to signal. TRUNDD, the fourth TRAIL receptor
may also function as a dominant negative by using a di¡erent
mechanism. Unlike TRID, TRUNDD contains a cytoplasmic
domain with a non-functional death domain. Consistent with
this, TRUNDD does not induce apoptosis, but instead, pro-
tects mammalian cells from TRAIL-induced death, suggesting
that it like TRID may serve as a dominant negative receptor
capable of attenuating TRAIL signalling in tissues where it is
highly expressed such as adult lung and fetal liver. However,
at this early stage we cannot rule out the possibility that
TRUNDD may engage other cell signalling pathways. Re-
gardless, these ¢ndings indicate that TRAIL signalling in
vivo is controlled by a complex receptor mechanism that ex-
ists to balance agonist and antagonist functions.
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